

Gender Innovation in Clinical Genetic Tests

2015. 08. 27
Chang Won Park
MacroGen

01 | NGS Technologies & Instruments



02 | Clinical Genomics & Personalized Medicine




03 | Gender Factors & BRCA1/2 test by MacroGen



01 NGS Technologies & Instruments




Chromosomes, Genes, DNA sequences




Note 1) A (Adenine), T (Thymine), C (Cytosine), G (Guanine)

Note 2) Source: <https://www.ornl.gov/ornlhome/>

Sanger sequencing vs. NGS





Sanger Dideoxy Sequencing



Next Generation Sequencing


Illumina Colonies (called “colonies”)



Each nucleotide has a dye with a different color


4-color fluorescent image of chip gathered after each chemical flows through

Register each image and follow color change of each colony to determine sequence



ECE/BioE 416
Lecture 24

Next Generation Sequencing



Sequencing DNA:

Previously –

- To figure out the genome sequence itself
- Structure and function of genes
- To elucidate the difference between individuals
- To associate the phenotype and the genotype

Currently –

- Still for the goals listed above
- But shifting toward the clinical purposes – detection of pathogenic variants
- Prediction or diagnosis of diseases
- Prognosis or companion diagnostics
- Needs for analyzing multiple genes or genomic regions simultaneously – NGS technology required



Illumina HiSeq2000/2500

- Sequencing by synthesis using reversible fluorescent dye terminators using clonal single molecule array;
- 50 to 100 base reads length
- ~ 800 million high-quality reads per flowcell (~100 million/lane)
- up to 600 Gb output per run



Illumina MiSeq

- Small capacity system. PE 2x150cycles in 27hours.
- 18-20Gb by 2x300bp
- PE 2 x 300bp – error rate for read1 about 2%; read 2 about 4%.
- In preparation – Longer insert size possible 1.5kb



Ion Torrent PGM

- Three types of semiconductor chips:
 - 314 – 10Mb
 - 316 - 100Mb
 - 318 – 1Gb
- Read length depends on base composition 100-400bp
- The fastest sequencing system on the market.



HiSeq X Ten, HiSeq X Five

- Factory-Scale WGS System
- sequence 16 whole human genomes at standard 30x coverage
- \$800 per genome
- generate 1.8 TB of sequence in under 3 days
- No multiplexing



HiSeq 3000, HiSeq 4000

- Daily throughput 200 ~ >400 GB





Figure 2: Advanced Patterned Flow Cell Design Enables Ultra-High Throughput. Patterned flow cells contain billions of nanowells at fixed locations, providing even cluster spacing and uniform feature size to deliver extremely high cluster density.

02 Clinical Genomics & Personalized Medicine




WGS with USD \$1000



Big Big Data from DNA Sequencing

- DNA sequence data between 2007 and 2010 equivalent to DNA sequence accumulated for the past 24 years



*As of February 8, 2011; estimates are subject to change.
Source: Cisco Systems, GenBank and AllianceBernstein*

Disease-Specific Information

Disease-Specific Information

- Molecular target
- Mechanism of action
- Prognosis

Disease Risk Prediction

- Acute disease risk (immediate treatment)
- Chronic disease risk (close monitoring)
- Susceptibility to environmental factors and lifestyle changes

Disease Risk Prediction

Patient's Molecular Information

- Genome
- Proteome (the full set of proteins produced by the genome)
- Metabolome (the full set of substances involved in metabolism)

Pharmacogenomic Information

Patient Pharmacogenomic (PGx) Information

- Issues with drug absorption, distribution, metabolism and excretion
- Potential toxicity risks


Companion Diagnostics

Drug Information—Companion Diagnostics (CDx)


- Drug with highest efficacy for disease
- Drug toxicity information

Personalized medicine: tailored treatments

Medicine of the present: one treatment fits all



Medicine of the future: more personalized diagnostics



Clinical Genomics in a New Paradigm



CYP2D6


- CYP2D6 involved primarily or substantially in the metabolism of 25% of drugs
 - Important for metabolism of TCAs, SSRIs, and antipsychotics
- Highly polymorphic gene (*CYP2D6*)
- Phenotypes
 - Poor metabolizer (PM)
 - Intermediate metabolizer (IM)
 - Extensive metabolizer (EM)
 - Ultrarapid metabolizer (UM)
- Phenotype prevalence:
 - Caucasian: 5%-10% PM, 35% IM, 7% UM
 - African American and Asian: 1%-3% PM

Pharmacogenetics

©2012 Mayo Foundation for Medical Education and Research. All rights reserved.



● “One size does not fit all.”



Companion Diagnostics – New Standard



Drug	Original Approval Date	Therapeutic Area	Biomarker
Arsenic Trioxide	2000	Oncology	PML/RARα
Tretinoin	1995		
Brentuximab Vedotin	2011	Oncology	CD30
Capecitabine	1998	Oncology	DPD
Fluorouracil	1998		
Cetuximab	2004	Oncology	EGFR; KRAS
Panitumumab	2006		
Crizotinib	2011	Oncology	ALK
Denileukin Diftitox	1999	Oncology	CD25/IL2
Exemestane	1999	Oncology	ER/PR
Fulvestrant	2002		
Letrozole	1997		
Imatinib	2003	Oncology	C-Kit, PDGFR, FIP1L1
Lapatinib	2007	Oncology	HER2
Pertuzumab	2012		
Trastuzumab	1998		
Everolimus	2009		
Nilotinib	2007	Oncology	Ph Chromosome
Dasatinib	2006		
Imatinib	2003		

**Erbix® EGFR
Colorectal/Lung**

**Iressa® Gefitinib KRAS
Colorectal/Lung**

**Tarceva® Erlotinib KRAS
Colorectal/Lung**

03 Gender Factors & BRCA1/2 test by Macrogen



- Personalized Medicine –
 - Age
 - Ethnicity
 - **Gender – Gender-specific disease susceptibility – Breast Cancer, Ovarian cancer**
 - Current physiological phenotypes
 - Life style
 - Working environment

BRCA1, BRCA2 Genes and Breast/Ovarian Cancer

- ▷ 3~5% of breast cancer caused by dominantly inherited mutations
- ▷ BRCA1/2 identified by linkage analysis (two decades ago), unstable, Alu (Large genes 81kb regions for BRCA1, 85kb for BRCA2, ave 10-15kb)
- ▷ Risk of breast cancer for a variant carrier : BRCA1 (65%) BRCA2 (45%) by age 70 (50-80% lifetime risk)
- ▷ Risk of ovarian cancer for a variant carrier: BRCA1 (39%) BRCA2 (11%) by age 70 (20-40% lifetime risk)
- ▷ Male BRCA1/2 carriers: 5.8-6.9% lifetime risk of breast cancer (still lower than ave risk of breast cancer in female)
- ▷ Male BRCA1/2 carriers: prostate cancer relative risk increased
RR 3.4-7.3
- ▷ 50% chance to inherit the mutation to female progenies
- ▷ Gender difference

BRCA1, BRCA2 Genes and Breast/Ovarian Cancer

- ▷ >3000 different variants in DB (public, [www.umd.be/BRCA1\(2\)](http://www.umd.be/BRCA1(2)))

- ▷ Preventive intervention
- ▷ Surgery – bilateral prophylactic mastectomy, bilateral prophylactic salpingo oophorectomy
- ▷ Enhanced screening – mammography, ultrasound
- ▷ Chemoprevention – vitamins, tamoxifen


- ▷ Current price range of the test – USD 300-5000



- ▶ Mother lost to ovarian cancer at the age of 56
- ▶ BRCA1 gene mutation
- ▶ 87% risk for breast cancer
- ▶ 50% risk of ovarian cancer
- ▶ Preventive double mastectomy
- ▶ Bilateral Salpingo-oophorectomy


“I made a strong choice that in no way diminishes my femininity.”

BRCA1/2 genetic test - MacroGen




- ▶ Both traditional (Sanger sequencing) and NGS-panel base
- ▶ MLPA – CNV analysis complement
- ▶ R&D to reduce the cost for broad **affordability**

BRCA1/2 genetic test - MacroGen



- ▶ Aiming at below USD 100 for the service price
- ▶ For free - low income classes
- ▶ Affordability and Availability Worldwide

BRCA1/2 genetic test - Macrogen



- ▶ **CLIA-certified lab in the US**
- ▶ **Global service availability**



기업정보

연구개발

사업분야

투자정보

홍보센터

인재채용

CS Center

HOME SITEMAP GLOBAL

Humanizing Genomics

One of the leading companies in DNA analysis including NGS

Clients from over 100 countries

사업영역

마크로젠은 인간게놈정보를 바탕으로 맞춤의학을 실현하고자 합니다

[자세히보기](#)

마크로젠 뉴스

[보도자료] 마크로젠, 영국 유니버시티 칼리지 런던대학...
 [보도자료] 제11회 마크로젠 여성과학자상, 서울대학교...
 [공고] 외부회계감사인 변경

[자세히보기](#)

연구소

마크로젠은 지노믹스 및 맞춤의학을 위한 3개의 핵심 연구소를 운영하고 있습니다

[자세히보기](#)



01 회장인사말

마크로젠 홈페이지를 방문해주셔서 감사합니다. 21세기가 인류에 전해준 첫 번째 메시지는 '인간 지능지도의 완성'이었습니다.

사회공헌

마크로젠은 함께 살아가는 세상을 만들어 갑니다. 마크로젠은 희망을 만들어 갑니다.

근보회 | 과학자상 | 여성과학자상



World Top-Class Sequencing Capacity



Next Generation Sequencing Instruments

over 18,000 human genomes per year at the price of \$1000 per genome



Miseq/HiSeq 2500
HiSeq X/HiSeq 4000

IonPGM-Dx
IonProton/IonPGM

PacBio RSII

Over 60 units of
the most advanced
sequencing platforms

Thank You for Your Attention.




Next Generation Sequencing

- Whole Genome Sequencing
- Exome Sequencing
- Transcriptome Sequencing
- Epigenome Sequencing
- Metagenome Sequencing



Capillary Electrophoresis Sequencing

- Standard Sequencing
- EZ-Seq Service
- Metagenome Sequencing
- Microsatellite Analysis
- Primer Walking



Microarray

- Illumina
- Agilent
- Affymetrix



Oligonucleotide Synthesis

- Oligo DNA
- Modified / Labeled Oligo



Genetically Engineered Mouse

- Transgenic Mouse
- Knock-out Mouse